Anti-Diabetic Drugs Market Posts Strong Growth in India
The anti-diabetic drugs market in India grew about 21% in September per one dataset and 16.1% per another. What drove it, including GLP-1 generics.
Read More
Biopharma SHAKTI Gets a Strong Start With 25 Trial Sites
Biopharma SHAKTI gets a 25-site clinical trial pilot as NIPER Raebareli and AstraZeneca India sign an MoU. What the pilot tests and what is undisclosed.
Coronary Stent Quality Under Review: Critical Test for Makers
Coronary stent quality is under government review in India. What tighter oversight could mean for makers and hospitals, and what is still unverified.
Perjeta Biosimilar Pebrilzo Gets Strong Boost After Settlement
A Perjeta biosimilar gets dates: Biocon says its Genentech settlement allows Pebrilzo in the EU and UK in Q1 2027 and the US in Q3 2028, subject to approvals.
Injectable Drug Contamination: Par Health Issues a Second Particulate Recall in a Week
Injectable drug contamination: Par Health recalls 22 argatroban lots days after two Brevital lots. A side-by-side look at both notices and open questions.
Viking Opens SUNRISE Trials of Oral VK2735, a Bold Push With Real Hurdles
Viking SUNRISE trials of oral VK2735 start in adults with obesity, with 68 weeks of treatment. How the tablet and injection programmes fit and the hurdles.
Agomab Doses First Patient in Ontunisertib Crohn’s Disease Phase 2b Trial: A Pivotal Step
Ontunisertib Crohn’s disease Phase 2b trial opens: first patient dosed in NOV-ERA, about 320 adults. The drug is unapproved and efficacy is unproven.
Abram Scientific DARPA Contract: Bold Win for Rapid Portable Blood-Coagulation Testing
Abram Scientific DARPA contract of up to $8.3M backs CoagCare, a portable clotting test. It is not FDA-cleared; speed claims are the company’s.
Google Flo Health Partnership: Powerful Step Linking Cycle Tracking and Wearable Data
Google Flo Health partnership links cycle tracking with wearable data from early 2027. The investment amount is undisclosed and the features are wellness tools.